Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H24NO2S.I |
Molecular Weight | 445.358 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[I-].C[N+]3(CCC(O)(C1=CC=CS1)C2=CC=CC=C2)CCOCC3
InChI
InChIKey=IOFXEUZPIIUQAG-UHFFFAOYSA-M
InChI=1S/C18H24NO2S.HI/c1-19(11-13-21-14-12-19)10-9-18(20,17-8-5-15-22-17)16-6-3-2-4-7-16;/h2-8,15,20H,9-14H2,1H3;1H/q+1;/p-1
Tiemonium (often used in a form of iodide or methylsulphate salt) is a muscarinic acetylcholine receptor antagonist, which is available in Asia (mainly Bangladesh) for the alleviation of muscle spasms of the intestine, biliary system, uterus and urinary bladder in gastrointestinal, biliary, urinary and gynecological diseases.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094109 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
PubMed
Title | Date | PubMed |
---|---|---|
Orofacial dyskinesia associated with tiemonium. | 2007 Dec |
|
Direct asymmetric catalytic thienylaluminum addition to ketones: a concise approach to the synthesis of (S)-tiemonium iodide. | 2009 Aug 6 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
6,7-Difluoro-1,4-dihydro-1-methyl-4-oxo-3-quinolinecarboxylic acid, a newly designed fluorescence enhancement-type derivatizing reagent for amino compounds. | 2010 Mar |
Patents
Sample Use Guides
Recommended oral dose of tiemonium (in form of methylsulphate salt) tablet is 2-6 tablets (100-300 mg) daily in divided dosage as required. Tiemonium can be also given as an injection (5 or 10 mg) three times daily, through Intravenous route or Intramuscular route. Suppository: recommended dose is 1 suppository (each suppository contains 20 mg methylsulphate salt) two or three times daily, through rectal route.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25343691
Human colon cancer cell lines, LOVO, were incubated in 2 ml of fresh complete medium containing 10(-2) M tiemonium methylsulfate for five days. Under the tested concentration tiemonium methylsulfate lead to a decrease of cell proliferation.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A03DA07
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
||
|
WHO-VATC |
QA03DA07
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
||
|
WHO-VATC |
QA03AB17
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
||
|
WHO-ATC |
A03AB17
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
||
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB11031MIG
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
FZ2LZ7U304
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
DB13666
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
DTXSID00875078
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110651
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
Tiemonium iodide
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
C75286
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
72142
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
100000082188
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
144-12-7
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
205-616-5
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
1543
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
C003602
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | |||
|
m10857
Created by
admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SUBSTANCE RECORD